Brazil’s Health Regulatory Agency has issued a marketing authorisation for the dengue fever vaccine developed by the Butantan Institute. It is the world’s first immunisation product against the disease that requires only a single administration. The news was reported by
Band News, a TV BRICS partner.
The vaccine has been approved for use in the population aged between 12 and 59. It provides protection against all four serotypes of the dengue virus. Immunity is expected to last for five years.
It is noted that the efficacy against symptomatic dengue is 74.4 per cent, while efficacy against severe forms of the disease reaches 91.6 per cent. The product was developed using live attenuated virus technology.
The Butantan Institute has 1 million ready-to-use doses of the vaccine, according to
Brasil de Fato, a TV BRICS partner. More than 30 million doses are planned for production in 2026. The inclusion of the vaccine in the national schedule of the Unified Health System is expected in early 2026.
As stated on the Brazilian government’s website, the epidemiological situation improved in 2025: the number of cases fell by 75 per cent compared with the previous year. The development of vaccine was carried out in cooperation between the Ministry of Health and a Chinese company.
Photo: MargJohnsonVA /
iStock
Самые
актуальные новости стран БРИКС https://tvbrics.com